Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 32

The DOI matches its Crossref record.

Tools for causality assessment in drug-induced liver disease

Tillmann, Hans L., Suzuki, Ayako, Barnhart, Huiman X., Serrano, Jose, Rockey, Don C. · 2019 · Current Opinion in Gastroenterology

Abstract

PURPOSE OF REVIEW: There are three liver-specific causality assessment tools currently available to guide clinical diagnosis of Drug-Induced Liver Injury (DILI): Roussel-Uclaf Causality Assessment Method (RUCAM), Digestive-Disease-Week Japan 2004 scale (DDW-J), and Clinical Diagnostic Scale (CDS). The purpose of this review is to assess these tools and discuss how to improve the causality assessment process as a whole. RECENT FINDINGS: Existing DILI-specific causality assessment tools are surprisingly similar and exhibit only minor differences in point allocation. But difference in threshold for likelihood of being DILI. We reviewed the literature on currently used causality assessment tools, identified areas for future improvement, and herein propose approaches for refinement. Opportunities to improve current models, as well as the assessment process, in general, include in particular provision of more precise clinical detail and to perhaps add new components to scoring systems. For example, the incorporation of drug-specific clinical signature patterns, accounting for a drug's inherent hepatotoxicity potential, and/or incorporation of other drug properties to scoring systems may allow enhancement. Further, more systemic exclusion of competing diagnoses is needed. Finally, causality assessment processes will likely benefit from a data-driven and computer-assisted approach. SUMMARY: Current tools used for DILI adjudication are imperfect. Avenues to improve these tools are described.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mog.0000000000000526

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 47

  1. Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 · DOI · Paper page
  2. Chen, 2014, A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the ’rule-of-two’ model, Arch Toxicol, 88, 1439, 10.1007/s00204-014-1276-9 · DOI
  3. Hunt, 2014, Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database, Regul Toxicol Pharmacol, 70, 519, 10.1016/j.yrtph.2014.09.007 · DOI
  4. Suzuki, 2017, Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury, Liver Int, 37, 1723, 10.1111/liv.13380 · DOI
  5. Chalasani, 2017, Idiosyncratic drug induced liver injury in african-americans is associated with greater morbidity and mortality ccompared to caucasians, Am J Gastroenterol, 112, 1382, 10.1038/ajg.2017.215 · DOI · Paper page
  6. Fung, 2001, Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999, Ther Innov Regul Sci, 35, 293
  7. Wilke, 2007, Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges, Nat Rev Drug Discov, 6, 904, 10.1038/nrd2423 · DOI · Paper page
  8. Church, 2018, In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials, Exp Biol Med (Maywood, 243, 300, 10.1177/1535370217740853 · DOI
  9. Regev, 2014, Drug-induced liver injury and drug development: industry perspective, Semin Liver Dis, 34, 227, 10.1055/s-0034-1375962 · DOI · Paper page
  10. Robles-Diaz, 2014, Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury, Gastroenterology, 147, 109.e5, 10.1053/j.gastro.2014.03.050 · DOI · Paper page
  11. Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study, Gastroenterology, 148, 1340.e7, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
  12. Fontana, 2014, Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset, Gastroenterology, 147, 96.e4, 10.1053/j.gastro.2014.03.045 · DOI · Paper page
  13. Lee, 2013, Drug-induced acute liver failure, Clin Liver Dis, 17, 575, 10.1016/j.cld.2013.07.001 · DOI · Paper page
  14. Hayashi, 2017, Death and liver transplantation within two years of onset of drug-induced liver injury, Hepatology, 66, 1275, 10.1002/hep.29283 · DOI · Paper page
  15. Fontana, 2015, Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury, Am J Gastroenterol, 110, 1450, 10.1038/ajg.2015.283 · DOI · Paper page
  16. Ortega-Alonso, 2018, Chronic liver injury induced by drugs and toxins, J Dig Dis, 19, 514, 10.1111/1751-2980.12612 · DOI
  17. Narjes, 2000, Effect of hospitalisation on liver enzymes in healthy subjects, Eur J Clin Pharmacol, 56, 329, 10.1007/s002280000142 · DOI
  18. Rosenzweig, 1999, Transaminase elevation on placebo during phase I trials: prevalence and significance, Br J Clin Pharmacol, 48, 19, 10.1046/j.1365-2125.1999.00952.x · DOI
  19. Douglas, 2013, Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink, BMJ, 346, f1936, 10.1136/bmj.f1936 · DOI · Paper page
  20. Danan, 1993, Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries, J Clin Epidemiol, 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
  21. Maria, 1997, Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis, Hepatology, 26, 664, 10.1002/hep.510260319 · DOI · Paper page
  22. Takikawa, 2003, Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting, ‘ Hepatol Res, 27, 192, 10.1016/S1386-6346(03)00232-8 · DOI · Paper page
  23. Rochon, 2008, Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury, Hepatology, 48, 1175, 10.1002/hep.22442 · DOI · Paper page
  24. Rockey, 2010, Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method, Hepatology, 51, 2117, 10.1002/hep.23577 · DOI · Paper page
  25. Alqahtani, 2015, Identification and characterization of cefazolin-induced liver injury, Clin Gastroenterol Hepatol, 13, 1328.e2, 10.1016/j.cgh.2014.11.036 · DOI
  26. Watanabe, 2004, Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales, Hepatol Res, 30, 148, 10.1016/j.hepres.2004.08.005 · DOI · Paper page
  27. Hanatani, 2014, A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale, Pharmacoepidemiol Drug Saf, 23, 984, 10.1002/pds.3603 · DOI · Paper page
  28. García-Cortés, 2011, Causality assessment methods in drug induced liver injury: strengths and weaknesses, J Hepatol, 55, 683, 10.1016/j.jhep.2011.02.007 · DOI · Paper page
  29. Danan, 2015, RUCAM in drug and herb induced liver injury: the update, Int J Mol Sci, 17, E14, 10.3390/ijms17010014 · DOI · Paper page
  30. Dalton, 2007, The role of hepatitis E virus testing in drug-induced liver injury, Aliment Pharmacol Ther, 26, 1429, 10.1111/j.1365-2036.2007.03504.x · DOI · Paper page
  31. Davern, 2011, Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury, Gastroenterology, 141, 1665.e1, 10.1053/j.gastro.2011.07.051 · DOI · Paper page
  32. Lucena, 2001, Comparison of two clinical scales for causality assessment in hepatotoxicity, Hepatology, 33, 123, 10.1053/jhep.2001.20645 · DOI · Paper page
  33. Aithal, 2000, Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions, J Hepatol, 33, 949, 10.1016/S0168-8278(00)80127-0 · DOI
  34. Whritenour, 2017, Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response, J Immunotoxicol, 14, 31, 10.1080/1547691X.2016.1254305 · DOI · Paper page
  35. Benesic, 2018, Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury, Clin Gastroenterol Hepatol, 16, 1488.5, 10.1016/j.cgh.2018.04.049 · DOI · Paper page
  36. Dragoi, 2018, Proteomics analysis of monocyte-derived hepatocyte-like cells identifies integrin beta 3 as a specific biomarker for drug-induced liver injury by diclofenac, Front Pharmacol, 9, 699, 10.3389/fphar.2018.00699 · DOI
  37. Russo, 2014, Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network, Hepatology, 60, 679, 10.1002/hep.27157 · DOI · Paper page
  38. Martinez, 2015, Clinical and histologic features of azithromycin-induced liver injury, Clin Gastroenterol Hepatol, 13, 369.e3, 10.1016/j.cgh.2014.07.054 · DOI
  39. Orman, 2011, Clinical and histopathologic features of fluoroquinolone-induced liver injury, Clin Gastroenterol Hepatol, 9, 517.e3, 10.1016/j.cgh.2011.02.019 · DOI
  40. Bessone, 2016, Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases, Liver Int, 36, 302, 10.1111/liv.12899 · DOI
  41. Nakaharai, 2016, Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score, Eur J Clin Pharmacol, 72, 1003, 10.1007/s00228-016-2064-7 · DOI
  42. Bermúdez, 2012, Espectro clínico de la hepatotoxicidad por nitrofurantoína en una serie clínica de 12 pacientes, Gastroenterol Latinoam, 23, 129
  43. Tillmann, 2016, A novel computerized drug induced liver injury causality assessment tool (DILI-CAT), Hepatology, 64, A320
  44. Cheetham, 2014, An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data, Pharmacoepidemiol Drug Saf, 23, 601, 10.1002/pds.3531 · DOI
  45. Rahnama-Moghadam, 2018, DILI associated with skin reactions, Curr Hepatol Rep, 17, 225, 10.1007/s11901-018-0414-x · DOI
  46. Björnsson, 2016, Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports, Hepatology, 63, 590, 10.1002/hep.28323 · DOI · Paper page
  47. McEuen, 2017, Associations of drug lipophilicity and extent of metabolism with Drug-Induced Liver Injury, Int J Mol Sci, 18, E1335, 10.3390/ijms18071335 · DOI · Paper page

Cited by

See all 32

Metadata

Authors
Tillmann, H. L., Suzuki, A., Barnhart, H. X., Serrano, J., & Rockey, D. C.
Venue
Current Opinion in Gastroenterology
Published
2019-05
Volume
35
Issue
3
Pages
183-190
ISSN
0267-1379
Cited by
32
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tools for causality assessment in drug-induced liver disease. https://app.cochat.ai/papers/10.1097/mog.0000000000000526
The paper
Tillmann, H. L., Suzuki, A., Barnhart, H. X., Serrano, J., & Rockey, D. C. (2019). Tools for causality assessment in drug-induced liver disease. Current Opinion in Gastroenterology. https://doi.org/10.1097/mog.0000000000000526

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.